What are the frequency, clinical features, and early outcomes associated with myopericarditis after COVID-19 mRNA vaccination in adolescents and young adults?
In this systematic review and meta-analysis of 23 studies, including 854 patients aged 12 to 20 years with vaccine-associated myopericarditis, the incidence of myopericarditis was higher in males after the second dose.
Although 15.6% of patients had left ventricular (LV) systolic dysfunction, only 1.3% had severe left ventricular systolic dysfunction (ejection fraction <35%); late gadolinium enhancement was found in 87.2% and 23.2% required ICU admission; however, no in-hospital mortality was observed.
These findings suggest broadly favorable outcomes of COVID-19 vaccine-associated myopericarditis in adolescents and young adults.
Published data on COVID-19 mRNA vaccine-associated myopericarditis in adolescents and young adults were derived from small case series, population-based national studies, or passive reporting systems. Evidence gathered from a larger international cohort is scarce.
To investigate the clinical features and early outcomes associated with myopericarditis after COVID-19 mRNA vaccination in a heterogeneous population of adolescents and young adults.
We searched PubMed and EMBASE data sources up to August 2022. No language restrictions applied.
We included observational studies and case series describing COVID-19 vaccine-associated myopericarditis in adolescents and young adults aged 12 to 20 years and reporting clinical features and early outcomes.
Data extraction and synthesis
Two independent investigators extracted relevant data from each study. A group meta-analysis was performed in a random effects model. Guidelines for reporting preferred reporting items for systematic reviews and meta-analyses and meta-analyses of observational studies in epidemiology were followed.